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Objective: To identify serum biomarkers through metabolomics approach that distinguishes physically inactive
overweight/obese women with metabolic syndrome from those who are metabolically healthy, independent of
body weight and fat mass.
Methods: We applied nuclear magnetic resonance spectroscopy-based profiling of fasting serum samples to
examine the metabolic differences between 78 previously physically inactive, body weight and fat mass matched
overweight/obese premenopausal women with and without MetS. MetS was defined as the presence of at least
three of the following five criteria: waist circumference ≥88 cm, serum triacylglycerol ≥1.7 mmol/L, and high density
lipoprotein cholesterol (HDL-C) <1.30 mmol/L, blood pressure ≥ 130/85 mmHg and fasting glucose ≥5.6 mmol/L).
Principal component analysis was used to reduce the large number of correlated variables to fewer uncorrelated
factors.
Results: Two metabolic factors were associated with MetS independent of BMI, fat mass, waist circumference and
physical activity/fitness. Factor comprising branched-chain amino acids (BCAA) and aromatic amino acids (AAA) and
orosomucoid was associated with all clinical risk factors (p < 0.01 for all).
Conclusion: Two metabolic factors distinguish overweight/obese women with metabolic syndrome from those
who are metabolically healthy independent of body weight, fat mass and physical activity/fitness. In particular,
factor comprising BCAA, AAA and orosomucoid seems auspicious biomarker determining metabolic health as it was
associated with all clinical risk factors. Further research is needed to determine the public health and clinical
significance of these results in terms of screening to identify those at greatest cardio-metabolic risk for whom
appropriate intervention strategies should be developed.
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Excess fat mass is often seen in conjunction with a con-
stellation of other cardiovascular risk factors such as
hypertension, dyslipidemia and hyperglycemia, so-called
metabolic syndrome (MetS) [1]. In recent years the
prevalence of MetS has increased directly with the epi-
demic of obesity [2]. Comparisons of obese and lean
subjects have evoked several hypotheses to explain the* Correspondence: shulin.cheng@jyu.fi
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bolic disorders including insulin resistance, systemic
low-grade inflammation [3], abdominal and ectopic fat
accumulation [4], and intestinal microbiota composition
[5]. Experimental evidence show that dysfunctional adi-
pose tissue have an unfavorable effect on metabolism
and thereby seem to underlie some of the obesity associ-
ated metabolic morbidities such as insulin resistance and
type 2 diabetes [6]. Furthermore, nutritional factors [7],
poor aerobic fitness [8] and physical inactivity [9] may
also contribute to the development of MetS.l Ltd. This is an Open Access article distributed under the terms of the Creative
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orders. In fact, preliminary evidence suggests that 16%
of the Finnish obese women [10] and ~ 20% of the gen-
eral obese population [11,12] are free from metabolic
disorders. Discovery of specific biomarkers in the blood
associated with MetS may reveal etiological pathways
and help to identify obese individuals at risk for disease.
In this study, we applied nuclear magnetic resonance
(NMR) spectroscopy to analyze circulating metabolites
to identify biomarkers that distinguish individuals who
are metabolically healthy from individuals with MetS,
independent of fat mass and physical activity/fitness.
Materials and methods
Study subjects
One hundred and three participants were recruited from
the city of Jyväskylä and its surroundings to participate
in EWI-study (Exercise and weight control intervention
to study aerobic exercise intervention for improving
physical fitness and weight control in overweight and
obese women, ISRCTN87529813). A study physician ex-
amined the physical condition of the subjects and ensured
that they met the inclusion criteria: 25–50 year old pre-
menopausal woman with a body mass index between 25
and 40 kg/m2, with a history of physically inactive life-
style (participating in regular exercise ≤ 2 times/wk
and ≤ 45 min/time), and without diagnosed musculo-
skeletal, hypertensive or cardiovascular conditions or
type I/II diabetes and without any medication affecting
glucose or lipid metabolism. The study protocol was
approved by the ethics committee of Central Finland
Health Care District. An informed consent was obtained
from all subjects prior to the assessments.
From those subjects who fulfilled the basic inclusion
criteria we identified individuals who had MetS defined
as the presence of at least three of the following five criteria
[13]: waist circumference ≥88 cm, fasting serum triacylglyc-
erol ≥1.7 mmol/L, high density lipoprotein cholesterol
(HDL-C) <1.30 mmol/L, glucose ≥5.6 mmol/L) and resting
blood pressure ≥ 130/85 mmHg. Women who had none of
the above (except waist circumference ≥88 cm) were cate-
gorized as metabolically healthy overweight/obese (MHO).
Thirty-six out of 103 overweigth/obese women were
characterized as MetS and forty-two as MHO. Twenty-
five had one of the above (in addition to waist circum-
ference ≥88 cm) and were discarded from the analysis.
Background information
Background information including medical history and
current health status was collected via self-administered
questionnaires. Food consumption and intakes of total en-
ergy and energy-yielding nutrients were assessed from
three day food records and analyzed using Micro-Nutrica
software developed by the Social Insurance Institution ofFinland and updated with data for new foodstuffs by the
study nutritionist [14]. Leisure time physical activity
(LTPA) of hours/week (participating in exercise such as
walking, jogging, running, gym fitness, ball games, swim-
ming, etc.) and physical inactivity hours per day (PIA, in-
cluding lying down and sitting time) were evaluated using
a validated self-administrated physical activity question-
naire described previously [15].
Fitness test
Maximum oxygen uptake (VO2max, ml/kg/min) was
assessed by bicycle ergometer. During tests, heart rates
were assessed using ECG and respiratory gases and ventila-
tion was measured using respiratory gas analyzer VIASYS
(Healthcare Inc. USA). A specialist physician was respon-
sible for monitoring ECG and blood pressure responses
during the test and recording subject’s signs and symptoms
throughout the test.
Respiratory gas exchange analysis
The REE (kcal/day) was assessed by respiratory gas ex-
change analysis (GEA) using a ventilated-hood system
(VIASYS Healthcare, Yorba Linda, CA, USA). Calibra-
tion of the GEA was carried out before each measure-
ment according to the manufacturer’s instructions. The
subjects were instructed to avoid any strenuous physical
activity and large, energy and protein rich meals for 24 h
before the laboratory visit. The subjects arrived at the la-
boratory in the morning after an overnight fast. After
relaxing in a measurement bed for 30 min, a ventilated
hood was placed over their heads. Their oxygen con-
sumption and carbon dioxide production were measured
for 20 min at 1 min intervals, in a supine position and in
a thermoneutral (22–24°C) environment. The first 5 min
of the data were discarded as artefacts. The REE was cal-
culated using the modified Weir equation [16].
Anthropometrical and body composition assessments
Body height (cm) was measured by using standardized
protocols (a wall-fixed measuring device). Body weight
(kg) and fat mass (FM, kg) were assessed using bio-
impedance (Inbody 720, Biospace Co. ltd Seoul, South
Korea). Precision of the repeated measurements expressed
as coefficient of variation was, on average, 0.6% for FM.
Body mass index (BMI) was calculated as weight/height2
(kg · m−2). Blood pressure (BP) was measured twice by
manual oscillometric methods in the morning after sitting
for 10 minutes after the subjects arrived at the laboratory.
Standing waist circumference was measured twice with a
tape measure and the mean value was used.
Blood samples
Venous blood samples for biochemical analyses were
taken in standardized fasting conditions in the mornings
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at -80°C until analyzed. Serum glucose, total cholesterol,
HDL, triacylglycerol, alanine amino transferase (S-ALAT);
aspartate amino transferase (S-ASAT) and gamma gluta-
myltransferase (GGT) were analyzed using the KONELAB
20XTi analyzer (Thermo Fischer Scientific inc. Waltham,
MA, USA). Insulin was determined by immunofluores-
cence using the IMMULITE Analyser (Diagnostic Prod-
ucts Corporation, Los Angeles). The homeostasis model
assessment of insulin resistance (HOMA-IR) index was
calculated as (fasting insulin concentration × fasting glu-
cose concentration)/22.5. The inter- and intra-assay CVs
were 2.0% and 3.7% for glucose and 11% and 3.4% for in-
sulin, respectively.
Serum metabolomics
All serum samples were analysed using a high-throughput
serum NMR metabolomics platform; the experimental
protocols including sample preparation and NMR spec-
troscopy have been described in detail elsewhere [17,18].
This methodology has recently been applied in various
large-scale epidemiological and genetic studies [19,20].
The NMR metabolomics methodology provides compre-
hensive quantitative information on various amino acids,
glycolysis intermediates, fatty acid composition and degree
of saturation and lipoprotein subclass distributions.
Data analyses
All data were checked for normality using the Shapiro-
Wilk’s W-test (PASW Statistics 18). If data were not
normally distributed, the natural logarithms were used.Figure 1 Hierarchical clustering of metabolomics data values in MHO
deviation from the overall mean concentration of the metabolite in each in
represent a decrease, and red squares an increase. Metabolite names are sh
(right) y-axis.Clinical characteristics and serum metabolites were com-
pared using an independent-samples t-test. To ensure that
the significant differences in metabolite levels between the
groups was not confounded by age, waist circumference
or BMI, analysis of covariance (ANCOVA) was used
adjusting for the above-mentioned variables. Metabolites
were denoted significant if the p-value was below 0.0005
to account for multiple testing of 100 independent tests.
All assayed metabolites are shown in Additional file 1:
Table S1 and Additional file 2: Table S2.
The metabolomics data was clustered utilizing hierarch-
ical clustering algorithm. First, the metabolite and other
values were metabolite-wise standardized to have 0 as a
mean and 1 as standard deviation. Second, the missing
values within the data were imputed with k-nearest neigh-
bour algorithm (k = 3). The resulted data values were clus-
tered using correlation distance and average linkage
methods (Figure 1).
Given the expected multicollinearity of metabolites,
we used principal component analysis (PCA) to reduce
the large number of correlated variables into fewer un-
correlated factors. PCA was performed on fasting levels
of amino acids, fatty acids, phospholipids, glycoproteins,
ketone bodies, and glycolysis and gluconeogenesis inter-
mediates. Varimax rotated factors with an eigenvalue ≥ 1
were identified and metabolites with a factor load ≥ 0.4
were reported as composing a given factor. Metabolomic
factor scores were calculated for each individual based
on the constructed scoring coefficients. Mean metabolite
factor levels were compared between MHO and MetS
groups with and without adjusting for age, BMI andand MetS groups. The heat map shows changes of x-fold standard
dividual belonging to either MHO or MetS group. Green squares
own on x-axis and individual subjects with adherent groups on
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levels were predictors for MetS using logistic regression
models in all subjects adjusted for age, waist circumfer-
ence and BMI. Finally, the networks between the metab-
olite factors and clinical risk factors were computed with
the Spearman correlation and illustrated using Himmeli
software [21]. Nominal statistical significance was de-
fined as p < 0.05.
Results
Clinical characteristics
The general characteristics of the study subjects are
given in Table 1. MetS group were older (p < 0.005), and
had higher BMI (p = 0.018) but no significant differences
in other anthropometric measures, REE, VO2max, LTPA
or dietary intakes of total energy and energy-yielding
nutrients between the groups were found. Systolic and
diastolic blood pressure, glucose, insulin, HOMA-IR,
triacylglycerol, HDL, total cholesterol, S-ASAT and S-
ALAT were all higher in MetS compared to MHO (p < 0.05
for all). After controlling for age, BMI and waist circumfer-
ence, the statistical significance remained for all.
Serum metabolites
A cluster analysis of serum metabolites implicated accu-
mulation of several fatty acid species, VLDL lipoprotein
subclasses, and glycoprotein and branched-chain amino
acids in subjects with MetS (Figure 1). All metabolite and
lipoprotein subclass quantities and statistics are shown in
Additional file 1: Table S1 and Additional file 2: Table S2.
To further identify relevant biomarkers associated with
Mets, we used principal component analysis. Eight meta-
bolic factors were identified composed of correlated me-
tabolites (Additional file 3: Table S3). Mean metabolite
component levels are shown in Table 2. There were sig-
nificant differences between MHO and MetS for factor 1
(branched-chain amino acids, phenylalanine, tyrosine
and orosomucoid) (p = 0.001) and factor 2 (total fatty
acids, omega-6 fatty acids, omega-7 and omega-9 fatty
acids, linoleic acid, mono-unsaturated fatty acids, total
phosphoglycerides, total phosphocholines) (p = 0.003).
After adjusting for age, waist circumference and BMI, the
level of statistical significance remained for both factors.
To verify that the association between metabolite factors
with MetS was not confounded by differences in age and
body fat, we performed a logistic regression analysis ad-
justed for age, waist circumference and BMI with MetS as
the dependent (outcome) variable. The results showed
that both factors were significantly associated with MetS
(p < 0.01 for both).
Finally, we performed a network analysis to explore
relationships between metabolite factors and clinical
risk factors (Figure 2). When examining all subjects to-
gether, factor 1 was associated with HOMA-IR, insulin,triacylglycerol, SBP, VLDL, BMI, waist circumference,
S-ALAT and inversely with HDL (p < 0.01 for all). Fac-
tor 2 and factor 3 were associated with IDL, LDL and
VLDL, while factor 2 was also associated with SBP and
triacylglycerol (p < 0.01 for all). Factor 7 was inversely
associated with BMI and waist circumference, while
factors 5 and 8 were inversely associated with insu-
lin and triacylglycerol, respectively (p < 0.01 for all).
All correlation coefficients and p-values are given in
Additional file 3: Table S3.
Discussion
In this study, we aimed to identify metabolite profiles
that distinguish physically inactive individuals who are
metabolically healthy from those who have MetS inde-
pendent of fat mass. We found that two metabolite factors
composed of 1) branched-chain amino acids (BCAAs),
aromatic amino acids (AAAs), orosomucoid and 2) several
species of fatty acids and phospholipids were associated
with MetS. Factor 1 was associated with all clinical risk
factors suggesting that serum amino acids and orosomu-
coid may be relevant biomarkers of obesity associated car-
diometabolic disorders.
The risk for developing metabolic disorders is propor-
tional to the degree of obesity [22]. However, a subset of
obese individuals seems to be protected from metabolic
disorders, despite having excess fat mass [23]. Conse-
quently, factors or mechanisms that explain the develop-
ment of MetS remain poorly understood, and are under
intense investigation since their understanding may help
design novel therapeutic strategies. The large variation
in susceptibility and age of onset in individuals with a
similar risk profile, suggests both genetic and environ-
mental factors contribute to development of metabolic
disorders [24]. Emerging evidence suggests several po-
tential mechanisms contributing to MetS including dys-
regulation of the hypothalamic-pituitary-adrenal (HPA)
axis due to chronic stress [25], dysregulation of the adi-
pose tissue and increased cytokine production [26], the
consequent systemic low-grade inflammatory state [27]
and increased cellular oxidative stress [28]. Recent stud-
ies suggest that all of these mechanisms may be acting at
different time during gestation, permanently reprogram-
ming the structure and physiology of the offspring to-
ward the development of metabolic disorders gradually
progressing into a constellation of metabolic disorders in
adulthood [29].
Recent studies have found that and elevated serum
BCAAs [30,31] are associated with metabolic disorders in-
dependent of body weight. Our results are in agreement
with the above-cited studies by showing that two factors
(factor 1: BCAA, AAA and orosomucoid and factor 2: sev-
eral species of fatty acids and phospholipids) were signifi-
cantly different between MHO and MetS, independent of







Age (years) 39.7 (7.6) 44.1 (6.1) 0.005
Height (cm) 165.5 (5.8) 164.7 (6.4) 0.565
Weight (kg) 79.1 (10.3) 83.1 (10.5) 0.095
BMI (weight (kg)/height (m)2) 28.9 (3.2) 30.6 (3.4) 0.018
Fat mass (kg) 29.0 (7.9) 32.2 (8.1) 0.071
Fat free mass (kg) 50.2 (5.5) 50.8 (5.5) 0.596
Waist circumference (cm) 95.7 (9.2) 99.2 (6.5) 0.061
Metabolic
SBP (mmHg) 122.0 (7.4) 136.4 (11.3) <0.0001
DBP (mmHg) 77.7 (6.1) 84.4 (6.7) <0.0001
GLUC (mmol/l) 5.1 (0.3) 5.5 (0.7) 0.0001
Insulin (μIU/l) 6.4 (2.9) 9.5 (3.6) 0.0001
HOMA-IR 1.6 (1.0) 2.3 (0.9) 0.002
HDL-C (mmol/l) 1.6 (0.3) 1.4 (0.3) 0.001
TRIGLY (mmol/l) 1.0 (0.3) 2.0 (0.9) <0.0001
CHOLtot (mmol/l) 4.7 (0.6) 5.6 (0.9) <0.0001
ALAT (IU/l) 13.3 (5.4) 18.8 (8.9) 0.003
ASAT (IU/l) 16.5 (5.6) 19.3 (6.8) 0.038
GGT (IU/l) 22.3 (13.8) 31.5 (13.6) 0.098
Energy expenditure and physical fitness
RMR (kcal/day) 1547 (200) 1505 (113) 0.337
VO2max (ml/kg/min) 31.7 (4.8) 31.3 (5.6) 0.758
LTPA (≤ ½ h/wk, %) 16 11 0.250
LTPA (1 h/wk, %) 62 46 0.671
LTPA (2 h/wk, %) 22 43 0.399
PIA (h/day) 16.1 (2.9) 16.1 (3.5) 0.965
Diet
Energy (kcal) 1791 (526) 1811 (555) 0.896
Protein (E%) 18.7 (3.9) 19.1 (3.9) 0.704
Carbohydrate (E%) 44.1 (11.2) 44.5 (8.7) 0.906
Fat (E%) 33.0 (6.4) 34.5 (11.4) 0.551
Saturated fat (E%) 12.4 (3.3) 13.0 (3.1) 0.537
Monounsaturated fat (E%) 11.1 (2.5) 11.2 (4.8) 0.914
Polyunsaturated fat (E%) 6.0 (2.2) 7.1 (4.7) 0.317
Data are given as mean (SD). P-values are for 2-tailed t-tests. MHO = healthy overweight/obese; MetS =metabolic syndrome; SBP = systolic blood pressure; DBP =
diastolic blood pressure; HOMA-IR = homeostatic model assessment of insulin resistance; S-ALAT = alanine amino transferase; S-ASAT = aspartate amino transferase;
S-GGT = gamma glutamyltransferase; RMR = resting metabolic rate, VO2max (maximum oxygen uptake); LTPA = leisure time physical activity, PIA = physical
inactivity, E% = percentage of total energy intake.
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creased the risk for MetS with similar magnitude (OR 2.90
vs. 2.67, Table 3) in the present study. However, the net-
work analysis (Figure 2) showed that factor 2 correlated
only with systolic blood pressure and serum lipids and li-
poproteins, whereas factor 1 was associated with all riskdeterminants, with most pronounced associations with tri-
acylglycerol, insulin, HOMA-IR, S-ALAT and HDL. These
findings indicate that elevated serum BCAAs and AAAs
are not only associated with insulin resistance as shown in
prior studies [32-34] but that they are also closely related
with lipid metabolism. This notion is in agreement with a







1) Amino acids and glycoproteins −0.34 (0.98) 0.43 (0.86) 0.001 0.001
2) Fatty acids and phospholipids −0.31 (0.82) 0.39 (1.08) 0.003 0.002
3) PUFA −0.16 (1.06) 0.21 (0.89) 0.120 0.631
4) Ketone bodies 0.07 (1.05) −0.09 (0.94) 0.497 0.377
5) Gluconeogenic intermediates 0.06 (0.97) −0.08 (1.04) 0.555 0.944
6) Miscellaneous 0.04 (0.97) −0.05 (1.05) 0.726 0.464
7) Miscellaneous 0.08 (0.99) −0.10 (1.01) 0.431 0.700
8) Miscellaneous 0.15 (0.75) −0.18 (1.23) 0.167 0.228
MHO =metabolically healthy overweight/obese; MetS =metabolic syndrome. Values are given as mean (SD); Factor 1(leucine, isoleucine, valine, tyrosine,
phenylalanine, orosomucoid); Factor 2 (total fatty acids, omega-6 fatty acids, omega7 and 9 fatty acids, linoleic acid, mono-unsaturated fatty acids, total
phosphoglycerides, total phosphocholines); Factor 3 (docosahexaenoic acid, polyunsaturated fatty acids, omega-3 fatty acids); Factor 4 (acetoacetate, 3-hydroxybutyrate);
Factor 5 (glutamine, glycine, pyruvate); Factor 6 (acetate, histidine); Factor 7 (creatinine, citrate); Factor 8 (urea). P-values are for the difference in mean metabolite
factor levels between MHO and MetS groups with and without adjustment for age, fat mass and waist circumference.
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tion of BCAAs increased lipogenic gene expression and
synthesis of triacylglycerol in the liver [35]. Furthermore,
the association of Factor 1 with S-ALAT also suggest po-
tential relationship for BCAAs and AAAs with fatty liver
[36], which is an important predictor of several compo-
nents of metabolic syndrome [37]. However, whether the
amino acids are causally implicated with increased serum
lipids and fatty liver in humans remains uncertain and
warrants further investigation.
It is unclear why factor 1 and its various components
are present in higher concentrations in individuals withFigure 2 A pruned visualization of the correlation network from un-a
to a surrogate linear predictor before computations. The color of the edge
vertices are colored as red and blue if all edges of the vertex are positive o
both negative and positive correlations with its neighbor, the vertex is colo
DBP = diastolic blood pressure; VLDL = triacylglycerol and cholesterol in very-l
low density lipoprotein particles; IDL = triacylglycerol and cholesterol in interm
tyrosine, phenylalanine, orosomucoid); Factor 2 (total fatty acids, omega-6 fatt
acids, total phosphoglycerides, total phosphocholines); Factor 3 (docosahe
5 (glutamine, glycine, pyruvate); Factor 6 (acetate, histidine); Factor 7 (creaMetS. The acute phase protein (orosomucoid) is induced
by infection and inflammation, and elevated plasma
levels have been found in patients with type 2 diabetes
[38]. Although the role of orosomucoid in the circula-
tion is not well understood, it has been suggested to
modulate immune responses to protect adipose tissue
from inflammation and metabolic dysfunction [39]. As
glucose [40] and lipid metabolites [41] are potential
stimulants for inflammatory pathways in both adipocytes
and macrophages, it is possible that the higher serum
orosomucoid concentration in MetS group is attributed
to higher level of these metabolic risk factors.djusted Spearman correlation analysis. Each variable was converted
s indicate the association magnitude as shown in the legend. The
r negative correlations, respectively. In the cases where the vertex has
red orange. Abbreviations: SBP = systolic blood pressure;
ow density lipoprotein particles; LDL = triacylglycerol and cholesterol in
ediate-density lipoprotein particles; Factor 1 (leucine, isoleucine, valine,
y acids, omega7 and 9 fatty acids, linoleic acid, mono-unsaturated fatty
xaenoic acid, polyunsaturated fatty acids, omega-3 fatty acids); Factor
tinine, citrate); Factor 8 (urea).
Table 3 Logistic regression model for individual factors
Factor OR 95% CI p-value
1) Amino acids and glycoproteins 2.90 1.40 - 6.03 0.004
2) Fatty acids and phospholipids 2.67 1.34 - 5.32 0.005
3) PUFA 1.14 0.62 - 2.09 0.667
4) Ketone bodies 0.77 0.43 - 1.39 0.385
5) Gluconeogenic intermediates 1.00 0.57 - 1.75 0.991
6) Miscellaneous 0.80 0.46 - 1.40 0.437
7) Miscellaneous 0.93 0.53 - 1.63 0.804
8) Miscellaneous 0.70 0.39 - 1.25 0.227
Component levels as predictors of MetS adjusted for age, BMI and
waist circumference.
Factor 1(leucine, isoleucine, valine, tyrosine, phenylalanine, orosomucoid);
Factor 2 (total fatty acids, omega-6 fatty acids, omega7 and 9 fatty acids, linoleic
acid, mono-unsaturated fatty acids, total phosphoglycerides, total phosphocholines);
Factor 3 (docosahexaenoic acid, polyunsaturated fatty acids, omega-3 fatty acids);
Factor 4 (acetoacetate, 3-hydroxybutyrate); Factor 5 (glutamine, glycine, pyruvate);
Factor 6 (acetate, histidine); Factor 7 (creatinine, citrate); Factor 8 (urea).
OR = odds ratio.
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term leisure-time physical activity is associated with low
BCAA concentration [42], and high muscle BCAA deg-
radation [43]. Furthermore, it has been shown that high
intrinsic aerobic endurance capacity is associated with
higher resting metabolic rate, improved signature of
muscle BCAA degradation and lower risk for MetS [44].
In the current study, all participants were physically in-
active, had similar aerobic fitness and resting metabolic
rate. Furthermore, although VO2max was inversely asso-
ciated with triacylglycerol, HOMA-IR, BMI and waist
circumference, no associations with metabolite factors
were found. Dietary patterns are also significant determi-
nants of the circulating levels of metabolites during fast.
In the current study, no differences were found in diet-
ary energy or energy yielding nutrient intakes. Thus, it is
unlikely that the higher level of factor 1 and it various
components can be explained by low level of physical
activity or poor cardiorespiratory fitness or dietary in-
take. However, it could be that some biological/genetic
difference in BCAA catabolism reflects the circulating
BCAA concentrations in the present study. Since tissue
biopsies were not obtained in the present study, we were
unable to measure genetic variations of the genes encod-
ing BCAA catabolic enzymes in skeletal muscle or adi-
pose tissues, and thus we cannot verify whether the
differences in amino acid concentrations between the
groups were attributable to subtle alterations in expres-
sion of the genes in BCAA catabolic pathway.
Although, the biological basis and clinical feasibility of
MetS are still debatable [45], in the present study serum
metabolite profiles were significantly different between
the MHO and MetS. Consequently, our results tend to
suggest that serum BCAA, AAA, orosomucoid and fatty
acids may be relevant determinants of metabolic healthindependent of fat mass and physical activity. However,
our results must be interpreted in the light of the study
limitations. First, the cross-sectional study design does
not show temporal relationship between the studied
clinical risk factors and serum metabolites and therefore
causal relationship cannot be deduced but rather serves
to generate hypotheses. It is also important to note that
in general population, all individuals with the MetS do
not necessarily have all the features described in the
present study. Moreover, this study is also limited by the
relatively small number of participants and the fact that
the study participants only consist of Finnish women. Fi-
nally, although HOMA-IR is a widely accepted measure of
insulin resistance, other methods such as hyperinsulinemic-
euglycemic clamp technique is considered more robust
method to measure insulin resistance [46].
In summary, our results showed that two metabolite
factors were associated with MetS independent of BMI,
fat mass, waist circumference and physical activity/fitness.
Especially factor comprising BCAA, AAA and orosomu-
coid seems auspicious biomarker determining metabolic
health as it was associated with all clinical risk factors.
Further research is needed to determine the public health
and clinical significance of these results in terms of
screening to identify those at greatest cardio-metabolic
risk for whom appropriate intervention strategies should
be developed.
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Additional file 3: Table S3. Correlations between metabolite factors
and clinical risk factors.
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